Docoh
Loading...

ME 23andMe Holding

News

Pro users get this 30m faster
The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs
22 Oct 21
Biotech, News, Offerings, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
Jim Cramer Likes CVS And 23andMe, Considers This Stock 'Too Cheap'
20 Oct 21
Long Ideas, Media, Trading Ideas
On CNBC’s "Mad Money Lightning Round," Jim Cramer said that CVS Health Corporation (NYSE: CVS) is a good stock and its CEO Karen Lynch was "doing a great job." The stock
51 Biggest Movers From Friday
18 Oct 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
12 Health Care Stocks Moving In Friday's Intraday Session
15 Oct 21
Intraday Update, Markets, Movers
33 Stocks Moving In Friday's Mid-Day Session
15 Oct 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers
12 Health Care Stocks Moving In Friday's Pre-Market Session
15 Oct 21
Pre-Market Outlook, Markets, Movers
22 Stocks Moving in Friday's Pre-Market Session
15 Oct 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
9 Health Care Stocks Showing Unusual Options Activity In Today's Session
21 Sep 21
Options
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. Unusual trading activity could push option prices to exaggerated or underestimated levels.
Cramer Shares His Thoughts On AppHarvest, Rio Tinto And More
9 Sep 21
Small Cap, Media
On CNBC's "Mad Money Lightning Round," Jim Cramer said 23andMe Holding Co. (NASDAQ: ME) is trading at $8 and it should be higher.
23andMe Sponsored Study Titled '23andMe IPF Research Study (IPF)' Posted To ClinicalTrials.gov; Study Is Recruiting
31 Aug 21
News, FDA
https://clinicaltrials.gov/ct2/show/NCT05028894
66 Biggest Movers From Yesterday
18 Aug 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares surged 265.5% to close at $15.35 on Tuesday after the company received a written pre-investigational new drug (pre-IND) response from the FDA regarding MMS019.
12 Health Care Stocks Moving In Tuesday's Intraday Session
17 Aug 21
Intraday Update, Markets, Movers
48 Stocks Moving In Tuesday's Mid-Day Session
17 Aug 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares jumped 93% to $$8.10 after the company received a written pre-investigational new drug (pre-IND) response from the FDA regarding MMS019.
Benzinga's Top Ratings Upgrades, Downgrades For August 17, 2021
17 Aug 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Why 23andMe's Stock Is Trading Higher Tuesday
17 Aug 21
Price Target, Initiation, Analyst Ratings, Movers, Trading Ideas
23andMe Holding Co. (NASDAQ: ME) shares are trading higher by 6.6% at $7.77 Tuesday morning after Credit Suisse initiated coverage on the stock with an Outperform rating and announced a $13 price target.
Why 23andMe's Stock Is Trading Higher Tuesday
17 Aug 21
Price Target, Initiation, Analyst Ratings, Movers, Trading Ideas
23andMe Holding Co. (NASDAQ: ME) shares are trading higher by 6.6% at $7.77 Tuesday morning after Credit Suisse initiated coverage on the stock with an Outperform rating and announced a $13 price target.
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Credit Suisse Initiates Coverage On 23andMe Holding with Outperform Rating, Announces Price Target of $13
17 Aug 21
News, Price Target, Initiation, Analyst Ratings
Credit Suisse analyst Tiago Fauth initiates coverage on 23andMe Holding (NASDAQ:ME) with a Outperform rating and announces Price Target of $13.
'Halftime Report' Traders Advise Viewers On Medtronic, 23andMe And More
13 Aug 21
Media, Trading Ideas
On CNBC's "Fast Money Halftime Report," Pete Najarian said Medtronic PLC (NYSE: MDT) is really well run and it has a great free cash flow and unbelievable balance sheet.
Stocks That Hit 52-Week Lows On Friday
13 Aug 21
News, Intraday Update, Markets, Movers, Trading Ideas
Friday morning, 94 companies reached new 52-week lows.

Press releases

Pro users get this 30m faster
23andMe Agrees to Acquire Lemonaid Health
22 Oct 21
M&A, News, Press Releases
Acquisition provides telemedicine platform for 23andMe to advance its vision of individualized primary care that empowers consumers to live healthier lives 23andMe to host investor webcast today at 10:00 AM ET
23andMe to Report FY2022 Second Quarter Financial Results on November 10, 2021
20 Oct 21
News, Press Releases
SUNNYVALE, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) ("23andMe"), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal
23andMe to Present at the Wells Fargo Healthcare Conference
1 Sep 21
News, Press Releases
SUNNYVALE, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) ("23andMe"), a leading consumer genetics and research company, announced today that management will be participating in the Wells
23andMe Reports FY2022 First Quarter Financial Results
13 Aug 21
Earnings, Press Releases
First quarter revenue up 23% over prior yearStrong cash balance of $770 millionContinuing to advance therapeutics portfolio to drive future revenue growth SUNNYVALE, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) --
Hercules Capital Reports Second Quarter 2021 Financial Results
29 Jul 21
Press Releases
Record Year-to-Date Total Debt and Equity Commitments of $971.7 Million Record Year-to-Date Total Fundings of $634.0 Million Surpassed $12.0 Billion in Cumulative Total Debt Commitments since Inception Q2 2021 Net